Main Categories: Home Page Products Psoriasis Hair loss Vitiligo Acne Dermatitis Hyperhidrosis Tiredness Alarm Medications Phototherapy Common questions Support forum Online shop Site map Contact Sub Categories Home
Up
Eczema & Dermatitis
Dermatitis allergic
Atopic dermatitis info
Dermatitis atopic
Dermatitis skin care
Contact irritant
Eczema in children
Dyshidrotic pompholyx
Elidel warning
Poison Ivy
Pityriasis Alba
Lichen Simplex
Dermatitis FAQs Popular Products: 
Dermalight 80 UV phototherapy 
Aculas hair loss laser system 
Idromed-4 Iontophoresis hyperhidrosis 
General solarium beds and sun lamps 
Medications & tips for chronic skin conditions 
Tiredness & Fatigue Warning System | FDA warns about Elidel a common eczema treatment FDA Public Health Advisory
Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment
The FDA is issuing a public health advisory to inform healthcare providers and patients about a potential cancer risk from use of Elidel (pimecrolimus) and Protopic (tacrolimus), products that are applied to the skin. This concern is based on information from animal studies, case reports in a small number of patients, and how these drugs work. It may take human studies of ten years or longer to determine if use of Elidel or Protopic is linked to cancer. In the meantime, this risk is uncertain and FDA advises that Elidel and Protopic should be used only as labeled, for patients who have failed treatment with other therapies.
The FDA recommends that healthcare providers, patients and caregivers consider the following:
Use Elidel and Protopic only as second-line agents for short-term and intermittent treatment of atopic dermatitis (eczema) in patients unresponsive to, or intolerant of other treatments.
Avoid use of Elidel and Protopic in children younger than 2 years of age. The effect of Elidel and Protopic on the developing immune system in infants and children is not known. In clinical studies, infants and children younger than 2 years old treated with Elidel had a higher rate of upper respiratory infections than did those treated with placebo cream.
Use Elidel and Protopic only for short periods of time, not continuously. The long term safety of Elidel and Protopic are unknown.
Children and adults with a weakened or compromised immune system should not use Elidel or Protopic.
Use the minimum amount of Elidel or Protopic needed to control the patient’s symptoms. In animals, increasing the dose resulted in higher rates of cancer.
Elidel cream and Protopic ointment are topical immunosuppressant calcineurin inhibitors that are applied to the skin and are the only approved drug products in this class.
Animal studies have shown that three different species of animals developed cancer following exposure to these drugs applied topically or given by mouth, including mice, rats and a recent study of monkeys. These studies were conducted at doses higher than generally used by patients and the risk of cancer increased with increasing drug dose and duration.
In addition to an ointment, tacrolimus, also comes as a pill or by injection, this form is known as (Prograf). Prograf is approved to prevent liver or kidney transplant rejection. It is known to cause both skin cancers and lymphoma in humans by suppressing the body’s normal immune defenses against cancer. The cancer risk increases with higher doses and longer treatment courses of Prograf. Both Elidel and Protopic are sometimes absorbed through the skin, though usually at very low amounts. Occasionally, children who have been treated with Elidel or Protopic have had high blood levels of these drugs.
Protopic was approved in December 2000 and Elidel in December 2001. Since their approval, FDA has received reports of lymphoma and skin cancer in children and adults treated with Elidel or Protopic; whether the reported cancers are associated with these products has not been clearly established.
Based on the advice of the FDA Pediatric Advisory Committee, which met on February 15, 2005, to review these findings, FDA will require labeling changes for Elidel and Protopic, including the placement of a boxed warning about the potential cancer risk. In addition, FDA will work with the commercial sponsors of the drugs to develop and implement a Medication Guide (MedGuide) to provide this information and instructions about appropriate use of Elidel and Protopic to patients, their families, and caregivers. MedGuides are intended to be distributed by pharmacists with each prescription or refill of a medication.
Source: FDA web page  products for the treatment of dermatitis
We offer a variety of products for treatment of dermatitis. Please click here to see all products or here for the Dermalight80 for spot treatment of dermatitis. | 
 why Beat Psoriasis?
no prescription needed no doctors letter fast worldwide delivery lowest price guarantee easy online ordering highest service levels best quality products secure online ordering who are our clients? home & personal users hospitals & clinics dermatologists specialist doctors naturopaths good skin diet  See our Friends and Foes diet tip book here, don't pay for an expensive skin, psoriasis, vitiligo or acne diet elsewhere, click here for details. competitions For your chance to win $595 cash back on your purchase every month click here. frequent questions company FAQ psoriasis FAQ vitiligo FAQ acne FAQ eczema FAQ hair loss FAQ sitemap & search downloads psoriasis overview things to do psoriasis survey |
